Global Anemia Drugs Market Research Report- Forecast to 2022

Global Anemia Drugs Market Information, by Anemia Type (Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and others), by Route of Administration (Oral and Injectable), by Product Type (Biologics and Non-Biologics), End User (Hospitals and Self-Administered) - Forecast to 2022

ID: MRFR/Pharma/1859-HCR | February 2021 | Region: Global | 84 pages

Market Synopsis of Global Anemia Drugs Market:


Market Scenario:


Anemia is a set of conditions characterized by weakness, shortness of breath and a general tiredness due to a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood. The lowered hemoglobin results in a lowered ability of the blood to carry oxygen. There are three main types of anemia, i.e. due to blood loss, due to decreased or faulty red blood cell production and due to increased red blood cell breakdown. Anemia affects a quarter of people of the world and of the different types of anemia iron deficiency anemia comprises of the largest number of people affected, about 1 billion and resulting in approximately 215,000 deaths each year. Anemia is also more common in females than males. It also has a greater propensity to affect children, pregnant and lactating women and the elderly.


The global market for anemia drugs is growing at a good rate. The market driving factors are growth of geriatric population, increasing awareness, increasing focus of social healthcare on women health and particularly anemia, rise in accidents and cancer, rise in other risk factors such as diabetes, modern lifestyle induced stress, poor nutritional habits, rise in lactating and pregnant women in developing regions, intestinal infections etc.


The market constraints are poor absorption of drugs especially intravenous iron and the side effects associated with the treatment. Better nutrition due to rising per capita income is also a market limiting factor for anemic drugs.


The global market for Anemia Drugs is expected to be around US$21.4 billion and is expected to grow at a CAGR of 8.4% to reach US$34.7 billion by the end of forecast period.


Study Objectives Global Anemia Drugs Market:



  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global anemia drugs market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by anemia type, by route of administration, by Gender (Male and Female), by product type, by end users and other sub segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.


Global Anemia Drugs Market, by Anemia Type, 2015 (%): 


 Global Anemia Drugs Market Image


Intended Audience



  • Anemia drugs Manufacturers

  • Anemia drugs Suppliers

  • Private Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Government Research Laboratories

  • Contract Manufacturing Organizations


Key Players for Global Anemia Drugs Market:


Some of the key players in this market are: Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company and others.


Market Segments:


Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration; market is segmented into oral and injectable. On the basis of gender; market is segmented into male and female. On the basis of product type; market is segmented into biologics and non-biologics. On the basis of end users; market is segmented into hospitals, self-administered and others.


Regional Analysis of Global Anemia Drugs Market:


Globally America is the largest market for anemia drugs followed closely by Europe. However it must be noted that the Asia pacific region is the fastest growing region and is poised to overtake the developed regions market soon. The Middle East and African market will also witness good growth rates. The chief cause for the greater growth of developing regions market is the rise of geriatrics population, unmet medical needs and social health schemes launched by governments and other bodies. The awareness towards women health and changes in social conditions is also fuelling the demand for anemic drugs.


The report for Global Anemia Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.



Frequently Asked Questions (FAQ) :


Anemia Drugs Market is projected grow at approximately 8.4% CAGR during the assessment period (2016-2022).

The valuation of the Global Anemia Drugs Market is estimated to increase to USD 34.7 BN by the end of 2022.

Increasing awareness and rising focus on women’s health, Rise in lactating and pregnant women, and Consistent healthcare advancement initiatives and awareness efforts are the major tailwinds pushing the growth of the Global Anemia Drugs Market.

North America holds the largest share in the Global Anemia Drugs Market, followed by Europe and the Asia Pacific, respectively.

GlaxoSmithKline plc, Amgen Inc., Bluebird bio, GlycoMimetics Inc., Biocon, Regen biopharma Inc., Acceleron Pharma, Bayer AG, and Eli Lilly and company, are some of the major players operating in the anemia drugs market.

Table of Contents

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s five forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global Anemia Drugs Market, by Anemia Type

5.1 Introduction

5.2 Iron deficiency anemia

5.3 Sickle Cell Anemia

5.4 Aplastic Anemia

5.5 Hemolytic anemia

5.6 Pernicious Anemia

5.7 Others

6 Global Anemia Drugs Market, By Route of Administration

6.1 Introduction

6.2 Oral

6.3 Injectable

7 Global Anemia Drugs Market, By Product Type

7.1 Introduction

7.2 Biologics

7.3 Non-biologics

8 Global Anemia Drugs Market, By End User

8.1 Introduction

8.2 Hospital

8.3 Self-administered

8.4 Others

9 Global Anemia Drugs market, by Regions

9.1 Introduction

9.1.1 Americas

9.1.1.1 North America

9.1.1.2 South America

9.1.2 Europe

9.1.2.1 Germany

9.1.2.2 France

9.1.2.3 UK

9.1.2.4 Italy

9.1.2.5 Spain

9.1.2.6 Rest of Europe

9.1.3 Asia Pacific

9.1.3.1 Japan

9.1.3.2 China

9.1.3.3 India

9.1.3.4 Republic of Korea

9.1.3.5 Rest of Asia Pacific

9.1.4 Middle East & Africa

10 Company Landscape

10.1 Introduction

10.1.1 Mergers Acquisitions

10.1.2 Collaborations

10.1.3 Release/New Product Launches

10.1.4 Other (Expansion, Updates, Partnership)

11 Company Profile

11.1 Amgen Inc.

11.1.1 Company Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 GlaxoSmithKline plc

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financials

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bluebird bio

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financials

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.4 Biocon

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financials

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.5 GlycoMimetics Inc.

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financials

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Regen biopharma Inc.

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financials

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Bayer AG

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7 Acceleron Pharma

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Eli Lilly and company

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others

11.9.1 Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

12 Others

13 Appendix
List of Tables

TABLE 1 GLOBAL ANEMIA DRUGS MARKET, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL ANEMIA DRUGS MARKET, BY ANEMIA TYPE, 2013-2022 (USD MILLION)

TABLE 3 GLOBAL ANEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2013-2022 (USD MILLION)

TABLE 4 GLOBAL ANEMIA DRUGS MARKET, BY PRODUCT TYPE, 2013-2022 (USD MILLION)

TABLE 5 GLOBAL ANEMIA DRUGS MARKET, BY END USER, 2013-2022 (USD MILLION)

TABLE 6 GLOBAL ANEMIA DRUGS MARKET, BY REGION, 2013-2022 (USD MILLION)

List of Figures
FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL ANEMIA DRUGS MARKET, BY ANEMIA TYPE

FIGURE 4 GLOBAL ANEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 5 GLOBAL ANEMIA DRUGS MARKET, BY PRODUCT TYPE

FIGURE 6 GLOBAL ANEMIA DRUGS MARKET, BY END USER

FIGURE 7 GLOBAL ANEMIA DRUGS MARKET, BY REGION

FIGURE 8 GLOBAL ANEMIA DRUGS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)